From 7f05d3b6fd2d0e009ecb30b3f91057516f8c85a1 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 12:51:00 +0000 Subject: [PATCH] extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 +++++ ...ients-undermining-chronic-use-economics.md | 6 +++++ ...copenia-glp1-muscle-loss-elderly-risk.json | 24 +++++++++++++++++++ ...arcopenia-glp1-muscle-loss-elderly-risk.md | 14 ++++++++++- 4 files changed, 49 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..f38291874 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (challenge) +*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* + +Sarcopenic obesity risk from GLP-1 use may create NEW healthcare costs that offset cardiovascular and metabolic savings. In elderly patients, muscle loss combined with high discontinuation rates (64.8% within 1 year) produces a weight cycling pattern where fat is regained but muscle is not, potentially increasing fall risk, fractures, and disability—all of which are expensive Medicare costs. This directly challenges the cost-savings thesis by introducing a mechanism where the same drug that prevents CV events causes sarcopenic disability. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..2d64a4901 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* + +The high discontinuation rate creates a specific body composition trap: 15-40% of weight lost is lean mass, but upon discontinuation patients regain fat preferentially without muscle recovery. This means the most common outcome is not 'return to baseline' but 'worse than baseline'—same or higher fat mass, significantly lower muscle mass, creating sarcopenic obesity with increased disability risk. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json b/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json new file mode 100644 index 000000000..9cc39a4c1 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json @@ -0,0 +1,24 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 1, + "rejected": 1, + "fixes_applied": [ + "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md b/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md index de9ecdae9..2c779bcbe 100644 --- a/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md +++ b/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md @@ -7,9 +7,13 @@ date: 2025-07-01 domain: health secondary_domains: [] format: review -status: unprocessed +status: enrichment priority: medium tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,11 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"] + + +## Key Facts +- Natural aging reduces skeletal muscle mass by 12-16% +- Sarcopenic obesity prevalence in older adults: 10-20% +- 64.8% of GLP-1 patients discontinue within 1 year +- 15-40% of GLP-1 weight loss is lean body mass (some analyses suggest up to 60%) +- Next-generation GLP-1 compounds are being designed to improve muscle preservation